At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,062 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 1,062 participants.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMar 2011
Primary CompletionJun 2012
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartMar 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.4 years ago
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensiondrug
Brinzolamide ophthalmic suspension, 1%drug
Brimonidine tartrate ophthalmic solution, 0.2%drug